VivoSeq
Gastroenterology

Microscopic Colitis

7

Pipeline Programs↗

3

Active Trials↗

5

Companies Involved↗

Microscopic Colitis is an early-stage landscape with 7 programs across 5 companies. The most active players are Sanofi, Ferring, Takeda. 1 therapy is approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

6/100

Mech. Concentration

33/100

Completion Rate

67/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

1 program

Phase 2Ferring logo

Ferring

1 program

Phase 2Takeda logo

Takeda

1 program

Phase 3S

Salix

2 programs

ApprovedS

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

6

clinical trials

Recruiting2 · 33%
Completed2 · 33%
Terminated1 · 17%
Not yet recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remission
Recruiting·Sanofi logoSanofi·Phase 2·NCT07156175·54 enrolled
Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis
Recruiting·EEugene F Yen, MD·Phase 2·NCT04043897·10 enrolled
Efficacy and Safety of Budesonide MMX® vs. Budesonide CR for Induction of Remission in Microscopic Colitis
Not yet recruiting·UUniversity of Calgary·Phase 2·NCT05915104·80 enrolled
Budesonide for Induction of Remission in Incomplete Microscopic Colitis
Completed·—·Phase 3·NCT02142634·44 enrolled
Trial of Mesalamine for the Treatment of Active Microscopic Colitis
Completed·MMayo Clinic·Phase 2/3·NCT00952952·70 enrolled
Treatment of Microscopic Colitis
Terminated·NNorwegian University of Science and Technology·N/A·NCT00184171·105 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)